🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⁉️Have you already saved the dates for #PCRLV 2025? 📅 November 16–18, 2025 | London, UK and ⤵️ PCR fundamentals course November 15, 2025 ➡️Don’t miss the opportunity to be part of the vibrant #PCRLV community ⁦PCRonline 🫀⁩

What a kickoff to #NYValves2025! 🚀 From cutting-edge science to hands-on sessions, today was packed with innovation, education, and amazing connections. Here’s a glimpse of the excitement from Day 1! 🔥🫀 #CardioX #CardioTwitter #CardioEd #CardioResearch Juan F. Granada

✨We’re waiting for you at #NYValves2025 for an incredible and educational session on leaflet modification! 🔹 Live case demonstration 🔹 Expert panel discussion led by Didier Tchetche Philippe Genereux 🔹 Cutting-edge techniques Cardiovascular Research Foundation #TAVR #TAVI #cardiotwitter

🔍 New insights from the REPAIR Study! CRF Fellow Dr. Philipp von Stein presented data on TEER for atrial and ventricular secondary MR during a Featured Clinical Science session at #NYValves2025. The study was simultaneously published in JACC: Cardiovascular Interventions.

#EvolutFX implantation with #Basilica - leaflet modification technique live from Emory Healthcare with Didier Tchetche Philippe Genereux Cardiovascular Research Foundation #NYValves2025 Medtronic

Echocardiography findings from #TRISCEND II presented at #NYValves2025 Cardiovascular Research Foundation

#PCRLV is the global meeting point for heart valves (London, 16-18 November) 📥Want to submit? Deadline: 2 September (89% acceptance rate) 🫀7 LIVE Centres are confirmed, so join now and don't miss out! pcronline.com/Courses/PCR-Lo… P.S. Early-career practitioner? Choose the aortic,

👀First insights into the G5 system for #MitraClip and #TriClip at #NYValves2025

JUST OUT JACC Journals #JACC at #NYValves2025 our #HeartValveCollaboratory MULTIVALVE disease rapid communication on combined #AorticStenosis and #MitralRegurgitation. Lots to learn from diagnosis to treatment, from surgery to transcatheter to medical therapy. Congrats

Great cases and presentations from the Montefiore Heart team. Edwin Ho Andrea Scotti Pier Pasquale Leone Ulrich Jorde Manaf Assafin Montefiore Health System

What an unforgettable #NYValves2025! 🎉 With over 3,000 attendees from around the world, this year’s meeting was a celebration of innovation, collaboration, and cutting-edge science in structural heart care. 🫀✨ A huge thank you to our faculty, attendees, and supporters for

Important finding on CT and fluoro showing 2nd TAV in Redo #TAVR were 100% underexpanded despite procedural optimization with pre and post dilatation. Time to rethink lifetime management strategy and consider #TAVR explant in low risk pts to avoid redo TAVR PPM ? JACC Journals

10y outcomes on S3 #TAVR vs SAVR in intermediate risk pts in P2A S3i is out #NYValves2025! Tamim Nazif presented similar site reported ☠️ (~80% dead in 10y with mean age 80) and low reintervention (3 and 3.2%) between two groups among survivors. It gives us a good picture of the

Honored to present on behalf of EXPANDed Investigators at #NYV2025 the 1y echo core lab adjudicated outcomes of #MitraClip M-TEER in SMR pts with COAPT and non-COAPT like criteria: LVEF <20%, LVEDD >70mm, PASP >70mmHg. Similar procedural safety. 1y MR <=1+ 90% both groups!

M-TEER for challenging anatomies 📺pcronline.com/Cases-resource… (watch replay with your free My PCR acount) Learn how to manage challenging anatomies in mitral TEER (small left atria, large coaptation gaps, giant left atria) and the risks they pose. Build confidence in

My first time at #NYValves — and what an incredible experience! ✔️ A full room dedicated to live cases ✔️ Heart Team Arena dedicated to dynamic debates between leading surgeons and interventional cardiologists ✔️ Late-breaking clinical trial presentations ✔️ Innovation room ✔️

State-of-the-art in EuroIntervention Comprehensive review on bioprosthetic valve dysfunction after TAVI: mechanisms, diagnosis, and management. Midterm BVF incidence remains low (<5%), with SVD as the key driver. Durability appears comparable to SAVR. Julien Ternacle Philippe Pibarot